Alentis Therapeutics is a clinical-stage biopharmaceutical company that operates in the healthcare sector, specifically in the development of treatments for cancer and fibrotic diseases. The company is based in Basel, Switzerland, with a subsidiary for research and development in Strasbourg, France.

The company's primary focus is on the development of first-in-class monoclonal antibodies against Claudin-1 (CLDN1). CLDN1 is a protein that plays a crucial role in the progression of diseases like cancer and fibrosis. When these diseases occur, the expression of CLDN1 increases and it moves outside of its usual location, the tight junctions between cells. This exposed, non-tight junctional CLDN1 drives the growth of cancer and fibrosis in various organs.

Alentis' lead products are monoclonal antibodies that specifically target this exposed and non-junctional CLDN1. In simple terms, these antibodies are designed to bind to the CLDN1 protein, thereby blocking its harmful effects and treating the disease.

The company's business model revolves around the research, development, and eventual commercialization of these treatments. Alentis serves a global market of patients suffering from cancers and fibrotic diseases, with a particular focus on those with a stiff, nonpermeable extracellular matrix (ECM) and immune-evasive tumor microenvironment.

In terms of revenue generation, Alentis is likely to earn income through the sale of its treatments once they have been approved for use by regulatory bodies.

Keywords: Biopharmaceutical, Cancer Treatment, Fibrotic Diseases, Monoclonal Antibodies, Claudin-1 (CLDN1), Research and Development, Clinical Stage, Disease Pathogenesis, Extracellular Matrix (ECM), Immune-Evasive Tumor Microenvironment.